DEERFIELD, Ill. (AP) -- U.K. regulators will grant marketing approval to Horizon Pharma's arthritis combination pill, pending review of a few final documents, the company said Friday.
Duexis is used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, an inflammatory disease of the spinal bones. The pill combines a prescription-strength dose of ibuprofen with a dose of famotidine, which is intended to prevent stomach ulcers associated with ibuprofen.
Duexis was previously approved in the U.S.
Shares of Horizon Pharma Inc. fell 3 cents, or 1.2 percent, to $2.37.
Source: http://news.yahoo.com/horizon-pharma-gets-uk-nod-151918018.html
bracket vangogh yield crossbow airhead atherosclerosis steven tyler
No comments:
Post a Comment